Market Overview

Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

Related CPHD
Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid
Benzinga's Top Downgrades

In a report published Friday, Cantor Fitzgerald reiterated its Hold rating and $38.00 price target on Cepheid (NASDAQ: CPHD).

Cantor Fitzgerald noted, “CPHD continues to hit on target new product launches with the FDA clearance of the Xpert CT/NG test (announced yesterday after the close) before year-end 2012. The CT/NG test, which was launched in Europe (May 2012) and will begin shipping in January in the U.S., represents the first high-volume testing opportunity for CPHD and a meaningful growth driver medium-term, in our view. We are currently modeling ~$35mm contribution from new product launches in 2013 (including CT/NG, MTB/RIF in the U.S., Vaginitis, etc.) representing ~11% of our 20% top-line growth projection for 2013. With hospital capex spending and sustainable margin execution as our primary concerns near-term, we are maintaining our $38 PT and HOLD rating.”

Cepheid closed on Thursday at $32.70.

Latest Ratings for CPHD

Sep 2016BairdDowngradesOutperformNeutral
Sep 2016CitigroupDowngradesBuyNeutral
Sep 2016BTIG ResearchDowngradesBuyNeutral

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Reiteration Analyst Ratings


Related Articles (CPHD)

View Comments and Join the Discussion!